|Bid||20.49 x 1800|
|Ask||24.57 x 3000|
|Day's Range||20.62 - 21.24|
|52 Week Range||20.11 - 27.78|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-21.74%|
|Beta (5Y Monthly)||0.87|
|Expense Ratio (net)||1.02%|
Veeva Systems (NYSE: VEEV) today announced that Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, and data cleaning in their upcoming study for EsoGuard in patients undergoing standard of care screening for, and management of, Barrett's esophagus or esophageal adenocarcinoma.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previously disclosed, on January 28, 2021, the Company entered into a term sheet agreement for the settlement of a previously disclosed putative class action lawsuit commenced in November 2020, captioned Spritzer v. PAVmed Inc.,
The latest sanctions on Russia’s central bank are leaving custodians with tough questions.